All HHS Contracts — July 09, 2026

Spero's $49.2M cost-sharing contract from BARDA reduces profit potential compared to fixed-price awards, and $35.5M already outlaid implies significant revenue recognition but lower margins for a small disadvantaged business.

The $39.3M base contract from NIH/NCI includes options that could bring total value to $111.9M, offering ~$11.2M annual revenue if fully exercised, with cost-plus-fixed-fee pricing providing stable but capped margins.

Northwestern subawarded $20.2M of its $25.3M contract (80%) and Seattle Children's subawarded $12.4M of $26.4M (47%), diluting direct revenue and indicating complex program management with limited financial benefit to the prime.

A $25.3M BARDA contract to Arizona State University (2009-2022) had zero outlays recorded, indicating possible termination or unfunded scope, raising questions about BARDA's budget execution for biodefense R&D.

Spero Therapeutics' cost-sharing contract requires the company to share financial risk with BARDA, potentially compressing margins if costs exceed estimates, given the 8-year performance period (2018-2026).

Arizona State University's $25.3M BARDA contract with zero outlays suggests potential budget constraints or shifting priorities at BARDA, which could affect future biodefense R&D awards to other entities.

Two of five contracts (Northwestern University and Seattle Children's Hospital) are from NIH/NIAID for structural biology research, totaling $51.7M, creating agency and research area concentration risk for investors tracking NIH-funded entities.

All five contracts were awarded under full and open competition with no set-asides, meaning no preferential advantages for incumbents—re-competes could shift awards to competitors.

Technical Resources International's $111.9M total potential value from NIH/NCI drug development support offers a 2.8x upside from the base $39.3M if all options are exercised through 2032, signaling stable NIH investment in cancer R&D support services.

Spero Therapeutics' BARDA contract for biotechnology R&D aligns with pandemic preparedness priorities—if BARDA increases biodefense funding, Spero could see follow-on awards or modifications to the current $49.2M contract.

Seattle Children's Hospital and Northwestern University contracts for infectious disease structural biology (total $51.7M) indicate sustained NIH/NIAID investment—publicly traded biotech firms partnering with these institutions could benefit from subaward opportunities.

All five contracts are civilian HHS awards (NIH, BARDA) for biotechnology R&D and infectious disease research, with total value of $165.6M—three of five have cost-no-fee or cost-sharing pricing, indicating stable but low-margin government funding for health preparedness.

Two contracts (Northwestern University and Seattle Children's Hospital) totaling $51.7M are from NIH/NIAID for structural biology of infectious diseases, representing 31% of total digest value—this concentration highlights NIH's focus on pandemic preparedness.

{"entity"=>"Spero Therapeutics, Inc.", "reason"=>"Holds largest contract ($49.2M) in digest with cost-sharing risk and 2026 end date—revenue recognition and margin impact are key.", "trigger"=>"Q3 2026 earnings report for contract revenue impact; BARDA modification announcements before 2026 end"}

{"entity"=>"Technical Resources International, Inc.", "reason"=>"Base contract of $39.3M with options up to $111.9M through 2032—option exercises are a key catalyst.", "trigger"=>"NIH/NCI option exercise announcements for years 3-10 (next likely by 2025)"}

{"entity"=>"NIH NIAID budget", "reason"=>"Two contracts ($51.7M total) depend on NIAID funding for infectious disease research—budget cuts could reduce follow-on awards.", "trigger"=>"FY2027 NIH budget request released by OMB; Congressional appropriations for NIAID"}

{"entity"=>"BARDA biodefense R&D portfolio", "reason"=>"Arizona State University's zero-outlay contract raises questions about BARDA budget execution—new awards will signal agency priorities.", "trigger"=>"BARDA FY2027 contract awards for biotechnology R&D; any modification to Spero contract"}